Dendritic cells in cancer immunology and immunotherapy

被引:1214
|
作者
Wculek, Stefanie K. [1 ]
Cueto, Francisco J. [1 ]
Mujal, Adriana M. [2 ,7 ]
Melero, Ignacio [3 ,4 ,5 ,6 ]
Krummel, Matthew F. [2 ]
Sancho, David [1 ]
机构
[1] CNIC, Immunobiol Lab, Madrid, Spain
[2] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA
[3] Univ Navarra, Ctr Appl Med Res, Div Immunol & Immunotherapy, Pamplona, Spain
[4] Inst Invest Sanitaria Navarra, Pamplona, Spain
[5] Univ Navarra, Univ Clin, Pamplona, Spain
[6] Ctr Invest Biomed Red Canc, Madrid, Spain
[7] Mem Sloan Kettering Canc Ctr, Immunol Program, 1275 York Ave, New York, NY 10021 USA
基金
欧洲研究理事会; 欧盟地平线“2020”;
关键词
ANTIGEN CROSS-PRESENTATION; CD8(+) T-CELLS; IMMUNE-RESPONSES; ANTITUMOR IMMUNITY; BETA-CATENIN; FLT3; LIGAND; ANTICANCER CHEMOTHERAPY; COINHIBITORY RECEPTOR; I INTERFERON; VACCINES;
D O I
10.1038/s41577-019-0210-z
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Dendritic cells (DCs) are a diverse group of specialized antigen-presenting cells with key roles in the initiation and regulation of innate and adaptive immune responses. As such, there is currently much interest in modulating DC function to improve cancer immunotherapy. Many strategies have been developed to target DCs in cancer, such as the administration of antigens with immunomodulators that mobilize and activate endogenous DCs, as well as the generation of DC-based vaccines. A better understanding of the diversity and functions of DC subsets and of how these are shaped by the tumour microenvironment could lead to improved therapies for cancer. Here we will outline how different DC subsets influence immunity and tolerance in cancer settings and discuss the implications for both established cancer treatments and novel immunotherapy strategies.
引用
收藏
页码:7 / 24
页数:18
相关论文
共 50 条
  • [41] Genetically modified dendritic cells for cancer immunotherapy
    Ribas, A
    CURRENT GENE THERAPY, 2005, 5 (06) : 619 - 628
  • [42] Why are dendritic cells central to cancer immunotherapy?
    Colaco, CALS
    MOLECULAR MEDICINE TODAY, 1999, 5 (01): : 14 - 17
  • [43] Killer dendritic cells and their potential for cancer immunotherapy
    Nicolas Larmonier
    Jennifer Fraszczak
    Daniela Lakomy
    Bernard Bonnotte
    Emmanuel Katsanis
    Cancer Immunology, Immunotherapy, 2010, 59 : 1 - 11
  • [44] Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy
    Anguille, Sebastien
    Smits, Evelien L.
    Bryant, Christian
    Van Acker, Heleen H.
    Goossens, Herman
    Lion, Eva
    Fromm, Phillip D.
    Hart, Derek N.
    Van Tendeloo, Viggo F.
    Berneman, Zwi N.
    PHARMACOLOGICAL REVIEWS, 2015, 67 (04) : 731 - 753
  • [45] DNA sensing of dendritic cells in cancer immunotherapy
    Qian, Wei
    Ye, Jun
    Xia, Sheng
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2024, 11
  • [46] Engineering Dendritic Cells to Enhance Cancer Immunotherapy
    Boudreau, Jeanette E.
    Bonehill, Aude
    Thielemans, Kris
    Wan, Yonghong
    MOLECULAR THERAPY, 2011, 19 (05) : 841 - 853
  • [47] Killer dendritic cells and their potential for cancer immunotherapy
    Larmonier, Nicolas
    Fraszczak, Jennifer
    Lakomy, Daniela
    Bonnotte, Bernard
    Katsanis, Emmanuel
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (01) : 1 - 11
  • [48] Generation of mature dendritic cells for cancer immunotherapy
    Bellik, L
    Parenti, A
    Pantalone, D
    Pieri, L
    Ledda, F
    FASEB JOURNAL, 2003, 17 (04): : A669 - A669
  • [49] A primer on cancer immunology and immunotherapy
    Lotze, MT
    Papamichail, M
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (03) : 135 - 138
  • [50] Immunology and immunotherapy in gastric cancer
    Xiaqing Xu
    Jiaxing Chen
    Wenxing Li
    Chenlu Feng
    Qian Liu
    Wenfang Gao
    Meng He
    Clinical and Experimental Medicine, 2023, 23 : 3189 - 3204